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Dedra Jones Markovich3, Darla Mansfield3, Dorita Avila2, Amit N. Patel5, Santosh Kesari6
and Jorge Paz Rodriguez1

Abstract
Background: Multiple sclerosis (MS) is a progressively debilitating neurological condition in which the immune
system abnormally erodes the myelin sheath insulating the nerves. Mesenchymal stem cells (MSC) have been used in
the last decade to safely treat certain immune and inflammatory conditions.
Methods: A safety and feasibility study was completed on the use of umbilical cord MSC (UCMSC) as a treatment
for MS. In this 1-year study, consenting subjects received seven intravenous infusions of 20 × 106 UCMSC over 7 days.
Efficacy was assessed at baseline, 1 month and 1 year after treatment, including magnetic resonance imaging (MRI)
scans, Kurtzke Expanded Disability Status Scale (EDSS), Scripps Neurological Rating Scale, Nine-Hole Peg Test, 25-Foot
Walk Test, and RAND Short Form-36 quality of life questionnaire.
Results: Twenty subjects were enrolled in this study. No serious adverse events were reported. Of the mild AEs
denoted as possibly related to treatment, most were headache or fatigue. Symptom improvements were most
notable 1 month after treatment. Improvements were seen in EDSS scores (p < 0.03), as well as in bladder, bowel, and
sexual dysfunction (p < 0.01), in non-dominant hand average scores (p < 0.01), in walk times (p < 0.02) and general perspective of a positive health change and improved quality of life. MRI scans of the brain and the cervical spinal cord
showed inactive lesions in 15/18 (83.3%) subjects after 1 year.
Conclusions: Treatment with UCMSC intravenous infusions for subjects with MS is safe, and potential therapeutic
benefits should be further investigated.
Trial registration ClinicalTrials.gov NCT02034188. Registered Jan 13, 2014. https://clinicaltrials.gov/ct2/show/NCT02
034188
Keywords: Multiple sclerosis, Umbilical cord stem cells, Stem cell therapy, Multiple sclerosis treatment, Mesenchymal
stem cells
Background
Multiple sclerosis (MS) is an immune-mediated inflammatory disease in which the immune system progressively destroys its own myelinated axons in the central
nervous system, in episodes lasting from a few months to
many years in duration. The eventual demyelination and
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axonal degeneration can cause serious and debilitating
motor, sensory, balance and cognitive problems, disability, serious complications, and negatively impact quality
of life [1–3].
While there is no known cure for MS, up to 82% of
costs incurred by MS patients are spent on drugs [4].
Treatments available include steroids for temporary flareups, disease-modifying drugs, and drugs targeting specific symptoms. While these may reduce the frequency
of exacerbations and slow disease progression, none have
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myelin or nerve regenerative capability to restore the
cumulative damage already in place [5].
Mesenchymal stem cells (MSC) derived from bone
marrow, adipose, or other sources can exert inhibitory
effects on immune-mediated disease states [6–10]. In
particular, MSC derived from umbilical cord (UC) Wharton’s Jelly possess a high proliferative and expansive ability, an enhanced therapeutic activity compared to other
MSC [11–14], and superior production of growth factors that stimulate secretions responsible for therapeutic
potential [15].
The safety of MSC therapy for MS has been demonstrated in several trials [16–20]. We reported three subjects treated with MSC and stromal vascular fraction
with no adverse effects; all showed clinical improvements
in cognitive and motor function and presented no new
lesions on magnetic resonance imaging (MRI) [21]. More
recently, trials with placenta-derived MSC [22], or with
intravenous UCMSC [23] reported few mild or moderate adverse effects, as well as some improvement in
Expanded Disability Status Scale (EDSS) scores.
In this study, we sought to determine the safety and the
efficacy of allogeneic UCMSC treatment in subjects with
MS.

Methods
This open-label, single-arm, single-center phase 1/2
study was designed to assess the safety and efficacy of
the intravenous administration of UCMSC for the treatment of MS. The study was approved by the Panamanian
Institutional Review Board (Comité Nacional de Ética
de la Investigación) and registered in the ClinicalTrials.
gov database (NCT02034188). The study sponsor was
Translational Biosciences. All treatments were administered at the Stem Cell Institute in the Republic of Panama, under Protocol Number TBS-UCMSC-001. Safety
was defined as absence of treatment-associated adverse
events at 1, 3 months, and 1 year post treatment. Efficacy
was assessed with traditional MS evaluation instruments
and a quality of life questionnaire at follow-up intervals,
as detailed in the “Treatment protocol” section.
Subjects were enrolled under the following criteria:
men or non-pregnant women ages 18–55 diagnosed
according to revised McDonald criteria [24] for clinically-defined MS; an EDSS score of 2.0–7.0 assessed at
least 3 months after the last acute attack of MS; willingness to keep a weekly diary and undergo observation for
1 year, and provision of documented health insurance in
their home country. Enrolled subjects were not required
to refrain from taking other medications or supplements
prior to study entry.
Subjects were excluded if they presented active proliferative retinopathy, poorly controlled diabetes mellitus
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(glycosylated hemoglobin HbA1C > 8.5%), renal insufficiency (Creatinine > 2.5 mg/dL) or failure, infection
(white blood cell count of > 15,000 K/cumm and/or temperature > 38 °C), history of organ transplant, previous or
active malignancy, or cardiovascular conditions. All participants provided written informed consent before study
participation.
Treatment protocol

Complete medical history, medication history, and list of
concomitant medications were collected from all subjects
prior to any treatment. Subjects also underwent a complete physical examination, vital signs (heart rate, respiratory rate, temperature, and systolic and diastolic blood
pressure), a 12-lead electrocardiogram (ECG), and laboratory testing (complete blood count, serum chemistry)
at baseline. MS diagnosis was confirmed according to the
revised McDonald criteria. Enrolled subjects received
140 × 106 UCMSC intravenously over the course of seven
visits (20 × 106 UCMSC/day) separated by 1–4 days.
At each treatment visit, subjects were assessed for any
adverse events experienced since their last visit, received
a physical examination (vital signs pre- and post- infusion), and were reviewed for adverse events throughout
the visit.
Follow-up visits, scheduled at 1, 3 month and 1 year
post-treatment, could take place at either the Stem Cell
Institute or near the subjects’ place of residence, overseen
by a licensed medical professional. At all follow-up visits, any adverse events experienced since last visit were
reviewed, and subjects received a physical examination,
laboratory tests and a 12-lead ECG. Any concomitant
medications were reviewed.
Adverse events were reported in terms of their severity (mild, moderate, severe), relatedness (definitely,
probably, possibly, not likely and unrelated), action
taken (none, adjustment, interruption or discontinuation of treatment dosage), medications or therapy
taken (drug therapy, non-drug therapy, or none), and
outcome (not recovered/resolved, recovered/resolved,
recovering/resolving,
recovered/resolved
with
sequelae, fatal and unknown). Efficacy parameters
were assessed at baseline, at 1 month, and at 1 year,
and included time point measures for the Kurtzke
Expanded Disability Status Scale (EDSS), the Scripps
Neurological Rating Scale (SNRS), the Nine-Hole Peg
Test (9HPT), the 25-Foot Walk Test (25FWT), and the
RAND Short Form-36 (SF-36) quality of life (QOL)
questionnaire.
Gadolinium-enhanced MRI scans of the brain and
cervical spinal cord were taken at baseline and 1 year
after treatment, and were examined by a single independent radiologist blinded to the intervention.
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UCMSC preparation and culture

UCMSC in this study were produced by MediStem
Panama Inc. UCMSC were isolated from afterbirth tissue obtained after full-term, healthy births, donated by
consenting mothers. After screening for infection and
contamination, UCMSC were obtained from enzymatic
digestion of Wharton’s Jelly tissue after a primary culture process at 37 °C, 5% CO2 during 24 h. Cells were
expanded using alpha-MEM (Gibco Life Technologies, Grand Island, NY), supplemented with 10% FBS
(USFDA approved, Gibco Life Technologies, Grand
Island, NY), and 4 mM GlutaMax (Gibco Life Technologies, Grand Island, NY) in triple flasks under normoxic conditions. Cells were assessed between passages
two and three for meeting MSC criteria and absence
of contamination. Each enzymatic digestion step was
considered to be a passage. Cells were harvested after
5 passages (3–4 weeks after initiation of primary culture). MediStem Panama used the minimal criteria
established by the Mesenchymal and Tissue Stem Cell
Committee of International Society for Cellular Therapy [25]. Each lot was tested for sterility (fungus, mycoplasma, aerobes and anaerobes), endotoxin level below
3 EU/ml, and viability after thawing higher than 75%.
The approved cells expressed surface molecules CD105,
CD73 and CD90, and lacked expression of CD45 and
CD34, as determined by flow cytometry. UCMSC were
also tested for differentiation into adipocytes, chondroblasts, and osteoblasts in vitro using StemPro® media,
and stained with oil red, alcian blue and alizarin red,
respectively. Approved cells were suspended in a dextrose and saline solution for subsequent administration.
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Table 1 Demographics of subjects in the study
Demographic

N = 20

Age (years)
Mean (SD)
(Range)

41.15 (9.29)
(24–55)

Gender
Male

40% (8/20)

Female

60% (12/20)

Diagnosis
Relapsing remitting MS

75% (15/20)

Primary progressive MS

20% (4/20)

Secondary progressive MS

5% (1/20)

Disease duration (years)
Mean = 7.7
  < 3

25% (5/20)

  4–6

25% (5/20)

  7–9

30% (6/20)

  10–12

10% (2/20)

  16–18

5% (1/20)

  19–21

5% (1/20)

Ambulation status
Wheelchair

55% (11/20)

Walker

20% (4/20)

Bilateral cane

5% (1/20)

Unilateral cane

20% (4/20)

No assistance

45% (9/20)

Origin
White/Caucasian

65% (13/20)

African Descent

10% (2/20)

Middle Eastern

5% (1/20)

Other (1 each Hispanic, Brazilian, Panamanian, and multiracial: Hispanic/White/Native American)

20% (4/20)

Statistical analysis

SYSTAT version 13.1 (SYSTAT Software Inc., San Jose,
CA, USA) was used to analyze the data. Differences
between baseline and follow-up scores were examined
using paired t-tests, with Bonferroni and Dunn-Sidak
corrections where applicable. A p-value of p < 0.05 was
considered significant.

Results
Twenty subjects with MS provided informed consent and were enrolled into this feasibility study from
October 10, 2014 to February 18, 2015. Mean age of
enrollees was 41.15 (SD = 9.29) years; 60% (12/20)
were female (Table 1). Enrolled subjects were of multiple international origins, including the Republic of
Panama. The mean disease duration of enrollees was
7.7 years. Fifteen subjects (75%) had a diagnosis of
relapsing–remitting MS, four (20%) with primary progressive MS, and one (5%) with secondary progressive

MS. Eleven subjects (55%) required ambulation assistance (wheelchair, walker, or cane) at baseline. Five
subjects (25%) did not take any MS-specific medication
over the course of the study, 10 (50%) continued taking
their usual MS medications, one (5%) began using MSspecific medication during follow-up, and four (20%)
reduced their intake of MS-specific medication during
follow-up.
All subjects received all of the infusions specified by
the treatment protocol, and attended the 1- and 3-month
visits. Nineteen subjects were followed for 1 year: the
1-year visit was completed for 17/20 subjects, two subjects partially completed the 1-year requirements. One
subject was lost to follow-up.
All subjects survived the study, and there were no
reported serious adverse events (AEs). None of the
reported AEs (Table 2) required adjustment, interruption
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Table 2 Reported adverse events
Event

Count

Severity
Mild

Relatedness
Moderate

Severe

Not related

Not likely

Possibly

Probably

Definitely

Headache

19

18

1

0

1

1

16

1

0

Fatigue

19

19

0

0

0

2

17

0

0

Cardiovascular

8

8

0

0

2

2

4

0

0

Injury/accident

8

6

2

0

8

0

0

0

0

Gastrointestinal

4

2

2

0

1

2

1

0

0

Musculoskeletal

4

4

0

0

1

3

0

0

0

Infection

3

3

0

0

2

0

1

0

0

Feelings/sensations

3

3

0

0

0

2

1

0

0

Dizziness

2

2

0

0

1

1

0

0

0

Gynecological

1

0

1

0

1

0

0

0

0

Skin disorder

1

1

0

0

0

1

0

0

0

Total

72

66

6

0

17

14

40

1

0

or discontinuation of treatments. There were six moderate AEs, and 66 mild AEs. No AEs were ongoing at the
1-year follow-up visit. No AEs were classified as definitely related to study treatment. The most commonly
reported AEs were headache (18 mild and one moderate), and fatigue (19 mild), classified as possibly related to
treatment.
EDSS scores were recorded at baseline and 1 month
post-treatment for all subjects; scores at 1 year were
available for 17 of 20 subjects (Fig. 1). At baseline, EDSS
scores ranged from 2.5–7.0, with a mean score of 5.23
(SD = 1.50). At 1 month, the mean score decreased to
4.75 (SD = 2.00), a mean reduction of 0.48 (SD = 0.85) or
about one category. Scores reduced further at the 1-year

time point, to 4.62 (SD = 2.72), a mean reduction of 0.68
(SD = 1.49), a little more than one category. Differences
were statistically significant at 1 month (p < 0.03), and
1 year (p < 0.04) when compared to baseline.
SNRS scores were recorded at baseline and 1 month
post-treatment for all subjects; scores at 1 year were
recorded for 17 of 20 subjects (Table 3). The SNRS total
mean score rose slightly from 75.0 (SD = 11.9) at baseline to 75.5 (SD = 16.5) at 1 month post-treatment, and
decreased to 73.5 (SD = 19.5, N = 17) 1 year post-treatment. A statistically significant improvement (p < 0.01)
was seen for the bladder/bowel/sex dysfunction category
at 1 month from the baseline assessment (Fig. 2). A statistically significant worsening was seen in the study group

Fig. 1 Kurtzke Expanded Disability Status Scale (EDSS) mean scores. Possible scores range from 0 (no disability) to 10 (death resulting from MS
complications). Scores from 1.0 to 4.5 indicate an ability to walk without any aid, and scores from 5.0 to 9.5 indicate an impairment to walking.
N = 20 at 1 month (same as baseline), N = 17 at 1 year. Statistically significant changes between time points are indicated with their p-values. Error
bars represent standard deviations

Riordan et al. J Transl Med (2018) 16:57

in four categories compared to baseline: visual acuity
at 1 month (p < 0.02) and 1 year (p < 0.03), right upper
extremity motor function at 1 year (p < 0.02), right lower
extremity sensory function at 1 month (p < 0.03) and
1 year (p < 0.01), and left lower extremity sensory function at 1 month (p < 0.01).
The 9HPT was recorded for all subjects at baseline
and 1 month post-treatment; scores were available for
19 of 20 subjects at 1 year (one lost to follow-up). Overall, subjects saw improvements in their scores. Statistically significant improvements from baseline were seen
in non-dominant hand scores for both best (p < 0.01)
and average (p < 0.02) times at the 1-month assessment
(Fig. 3). The best score for the non-dominant hand was
37.56 s at baseline, 32.49 at 1 month (5.1 s improvement), and 31.55 at 1 year (6.0 s improvement). The average mean score for the non-dominant hand was 40.80 s
at baseline, 35.01 at 1 month (a 5.8 s improvement), and
34.09 (a 6.7 s improvement).
For the 25FWT, subjects were categorized into one
of four categories, based on their need for assistance to
complete the test (in order of increasing need): no assistance; cane; walker, and wheelchair. While scoring guidance for the 25FWT directs to use the average of the two
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completed trials, the minimum time was also analyzed
to enable inclusion of any/all subject(s) who completed
at least one full trial. At baseline, all 20 subjects were
available for the 25FWT, and 19 subjects were available
at 1 month (one did not take the test). At 1 year, results
were recorded for 17 subjects (two did not take the test;
and one was lost to follow up). Some subjects were unable to complete one or both trials due to ambulation status (two were wheelchair-bound at baseline, one at the
1-month and at 1-year follow-ups), or fatigue (one subject was fatigued at the 1-year follow-up).
At baseline, average time for the 25FWT Trial 1 was
17.43 s and 17.51 s for Trial 2 (Table 4). Overall mean
time was 17.47 s, and average minimum time was 15.85 s.
One month after treatment, average walk time for Trial
2 improved by 6.01 s, but average time for Trial 1 took
longer than baseline, as did overall mean time, and average minimum time. At 1 year, all walk times were reduced
when compared to baseline. Since not all subjects completed both trials of the 25FWT at a given time point,
and not all subjects completed all follow-ups, statistical comparisons between baseline and follow-up scores
could not include all subjects. Twelve subjects completed
Trial 2 of the 25FWT at the three follow-up time points

Table 3 Scripps neurological rating system (SRNS) component scores
SNRS component
Mentation and mood (normal = 10)

Visual acuity (normal = 5)*

Visual fields (normal = 6)

Eye movements (normal = 5)

Nystagmus (normal = 5)

Lower cranial nerves (normal = 5)

Motor function R upper extremity (normal = 5)*

Motor function L upper extremity (normal = 5)

Motor function R lower extremity (normal = 5)

Motor function L lower extremity (normal = 5)

DTR upper extremity (normal = 4)

DTR lower extremity (normal = 4)

Babinski sign L side (absent = 2)

Babinski sign R side (absent = 2)

Sensory R upper extremity (normal = 3)

Sensory L upper extremity (normal = 3)

Sensory R lower extremity (normal = 3)*

Sensory L lower extremity (normal = 3)

Cerebellar signs upper extremity (normal = 5)

Cerebellar signs lower extremity (normal = 5)

Gait trunk and balance (normal = 10)

Bladder, bowel, and/or sexual dysfunction (normal = 0)*

Total SNRS

*Statistically significant change, p < 0.05

Baseline

1 month

1 year

8.4 (2.28)

9.4 (1.57)

9.3 (1.69)

4.9 (0.45)

4.2* (1.35)

4.2* (1.24)

5.7 (0.73)

5.6 (1.05)

5.6 (0.79)

4.8 (0.62)

4.8 (0.62)

4.8 (0.66)

5.0 (0.00)

4.8 (0.62)

4.9 (0.49)

5.0 (0.00)

4.9 (0.45)

5.0 (0.0)

4.8 (0.62)

4.5 (0.89)

4.1* (1.44)

4.3 (0.98)

4.4 (1.14)

4.1 (1.44)

3.2 (1.66)

2.6 (1.82)

2.4 (1.91)

2.7 (1.81)

2.7 (2.03)

2.7 (2.23)

3.6 (0.95)

3.3 (1.22)

3.6 (0.79)

2.4 (1.35)

2.1 (1.62)

2.3 (1.61)

0.6 (0.94)

0.9 (1.02)

0.7 (0.99)

0.8 (1.01)

0.8 (1.01)

0.5 (0.87)

3.0 (0.00)

2.7 (0.47)

2.8 (0.56)

3.0 (0.00)

2.6 (0.50)

2.8 (0.56)

2.9 (0.31)

2.5* (0.51)

2.5* (0.72)

2.9 (0.31)

2.5* (0.51)

2.5 (0.80)

4.0 (1.52)

4.0 (1.52)

4.1 (1.60)

2.9 (1.46)

3.6 (1.87)

3.4 (1.77)

5.1 (2.74)

5.6 (3.17)

4.6 (3.69)

− 4.7 (2.52)

− 2.7* (2.89)

− 3.1 (3.31)

75.0 (11.90)

75.5 (16.54)

73.5 (19.52)
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Fig. 2 Scripps Neurological Rating Scale (SNRS) scores. Bladder, bowel and sexual dysfunction SNRS scores. The normal score is 0. A higher score on
the SNRS indicates a higher level of neurological functioning, with possible scores ranging from − 10 to 100. N = 20 at 1 month (same as baseline),
N = 17 at 1 year. Statistically significant changes between time points are indicated with their p-values

(baseline, 1 month and 1 year), with a statistically significant reduction (p < 0.02) in walk times found between
baseline and 1 month (Fig. 4).
Some subjects changed ambulatory status at the time
of the 25FWT at the 1-month visit: two subjects reduced
their dependence upon assistive devices (one from wheelchair to walker, one from walker to cane); one became
more dependent (from no assistance to a cane). At the
1-year visit, two subjects reduced their dependence upon
assistance devices from baseline to 1-year visit (one from
wheelchair to walker, one from walker to cane to no
assistance); two increased dependency (one from unilateral cane to walker, one from no assistance to cane). One
of the subjects, wheelchair-bound at baseline and thus
unable to complete the test then, was able to complete it
at the 1-month and 1-year follow-ups.
Scores for the RAND SF-36 test were recorded for all
subjects at baseline and 1 month, and for 17 of 20 subjects at 1 year post-treatment. Overall, subjects reported
improvements in their health during the study. Total
QOL scores increased over baseline for 15 subjects at
the 1 month follow up visit, while only five decreased.
At 1 year, total QOL score improved over baseline for
11 subjects, while six decreased (Fig. 5). At 1 month and
1 year, more than half of the subjects reported their condition as better or the same on all scale scores (Table 5).
At 1 month, more than 50% of subjects reported improvements on five of the eight scale scores (role limitationsphysical, energy/fatigue, emotional well-being, social
functioning, and general health), as well as health change;
45% (9/20) of subjects reported improvements in the
pain scale, and 35% (7/20) of subjects reported improvements in their physical functioning and role limitationsemotional. At 1 year, more than half of subjects reported

feeling better in five of the eight scales (physical functioning, role limitations-physical, energy/fatigue, emotional
wellbeing, and general health), as well as health change;
47% (8/17) reported improvements in their social functioning, 35% (6/17) in pain scale, and 29% (5/17) in role
limitations-emotional.
Statistically significant changes from baseline occurred
at both 1-month and 1-year assessments for the RAND
SF-36 role limitations-physical (p < 0.002 and p < 0.03,
respectively) and health change (p < 0.004 and p < 0.02,
respectively) categories. A statistically significant change
occurred from baseline at 1 month in the energy category
(p < 0.006) and the average score (p < 0.001). Bonferroni
corrections retained statistically significant differences
at 1 month in these four categories (p < 0.02). Most categories in the RAND SF-36 showed improvement over
the baseline at 1 month and 1-year evaluations, with the
exception of the 1-month physical function score. Most
categories scored highest at the 1-month evaluation with
the exception of the physical function category (Fig. 6).
Pre- and post-treatment MRIs from the brain and the
cervical spinal cord were reviewed qualitatively for every
subject. MRI was unavailable at the 1-year follow-up for
two subjects. Not all subjects had the second MRI taken
at exactly 1 year after treatment; there was some variation in completion of the second MRI, up to 4 months
after the 1-year mark. No common themes were detected
regarding number of lesions or disappearance of lesions.
Of the 18 subjects that did complete MRI both at baseline and at the 1-year follow-up, 15 (83.3%) showed no
disease progression or no new or active lesions. Two
subjects (11.1%) showed progression in their lesions.
One patient (5.6%) showed near complete resolution
of the plaques in the brain, in previously noted areas of

Riordan et al. J Transl Med (2018) 16:57
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Fig. 3 Nine Hole Peg Test (9HPT) for non-dominant hand. Best (a) and average (b) times for non-dominant hand. The 9HPT is an evaluation of arm/
upper extremity functionality or disability. A reduction in the test time from the reference time point signifies an improvement of upper extremity
function. N = 20 at 1 month (same as baseline), N = 19 at 1 year. Statistically significant changes between time points are indicated with their
p-values. Error bars represent standard deviations

Table 4 25-Foot Walk Test times

Baseline
1 month
1 year

Trial 1—average time

Trial 2—average time

Overall mean time

Average minimum time

17.43 (N = 18)

17.51 (N = 18)

17.47 (N = 18)

15.85 (N = 18)

16.18 (N = 15)

13.29 (N = 13)

15.70 (N = 15)

14.71 (N = 15)

29.19 (N = 18)

11.50 (N = 13)

abnormal signal intensity consistent with demyelinating
disease (Fig. 7).

Discussion
The demographics of this study correspond to those of
an expected MS population, where women are typically
affected twice as frequently as men, and most patients are
diagnosed between 20 and 40 years of age [26–29].

28.63 (N = 18)

28.01 (N = 18)

No Serious Adverse Events occurred in the study. One
single Adverse Event (AE), headache, was noted as probably related to treatment. Of the AEs denoted as possibly related to treatment, most were headache or fatigue.
Headache is a known complaint noted to occur during or
just after MSC infusions, most of which quickly resolve
[30]. Additionally, Foley et al demonstrated that patients
with MS commonly experience headache [31]. Thus,

Riordan et al. J Transl Med (2018) 16:57
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Fig. 4 25 Foot Walk Test (25FWT) 2nd trial scores. Subjects were asked to perform two trials of a 25-Foot Walk. Not all subjects completed both
trials, or performed these tests at all time points. In this figure N = 12, and statistically significant changes between time points are indicated with
their p-values. Error bars represent standard deviations

Fig. 5 RAND SF-36 quality of life scores compared to baseline. Scores for the RAND SF-36 question capture health change. Scores were compared
with baseline at the 1-month and 1-year visits. N = 20 at 1 month (same as baseline), N = 17 at 1 year

headache is not unexpected at the time of or just after
UCMSC infusions. Similarly, fatigue is one of the most
common complaints [32]. Fatigue appears in all ages and
phenotypes of MS [33–35] and is a primary determinant
of poor QOL [35], affecting both physical and mental
components independent of disability level [34]. Thus,
although fatigue is a possibly related AE in this study, it is
also a very common disability symptom of MS.
Enrolled subjects experienced an improvement in their
symptoms, which was most notable at 1 month after
treatment, and was sustained at 1 year in some cases
(Table 6). The potential durable benefit of UCMSC at
1 month, and sustained in some measures to 1 year, is in
stark contrast to current MS drug therapies, which are

required to be taken daily or weekly [36]. In addition, MS
drugs are known to carry side effects [37] not seen after
UCMSC infusions up to 1-year after treatment.
Previous studies using MSC treatment for MS have
reported improvements in EDSS scores [19, 22, 23, 38,
39]. In our case, the statistically significant (p < 0.03)
change in EDSS mean scores from baseline to 1 month
reflects a change in disability category, which could translate into an improved ability to walk and work a full day
with minimal, if any, assistance. Although other categories showed worsening typical of disease progression, the
bladder/bowel/sexual dysfunction category of the SNRS
showed statistically significant improvement at 1 month
(p < 0.05). This finding may be encouraging in that up to
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Table 5 RAND SF-36 changes in scores
Baseline to 1 month (N = 20)
Better
Physical functioning
Role limitations—physicala
Role limitations—emotional

Baseline to 1 year (N = 17)

Same

Worse

Better

Same

Worse

7 (35%)

4 (20%)

9 (45%)

10 (59%)

1 (6%)

6 (35%)

13 (65%)

6 (30%)

1 (5%)

11 (65%)

4 (24%)

2 (12%)

7 (35%)

10 (50%)

3 (15%)

5 (29%)

9 (53%)

3 (18%)

Energy/fatigueb

16 (80%)

1 (5%)

3 (15%)

11 (65%)

0 (0%)

6 (35%)

Emotional well-being

13 (65%)

2 (10%)

5 (25%)

10 (59%)

2 (12%)

5 (29%)

Social functioning

12 (60%)

2 (10%)

6 (30%)

8 (47%)

1 (6%)

8 (47%)

9 (45%)

5 (25%)

6 (30%)

6 (35%)

8 (47%)

3 (18%)

General health

11 (55%)

1 (5%)

8 (40%)

9 (53%)

2 (12%)

6 (35%)

Health changea

13 (65%)

6 (30%)

1 (5%)

11 (65%)

4 (24%)

2 (12%)

Pain

a

Differences between baseline and 1-month and 1-year scores statistically significant (p < 0.03)

b

Differences between baseline and 1-month scores statistically significant (p < 0.001)

Fig. 6 Changes in RAND SF-36 component scores. Changes in scores for all the RAND SF-36 categories. Asterisk denotes statistically significant
changes (p < 0.05) both at 1 month and 1 year post-treatment; degree denotes statistically significant change (p < 0.05) at 1 month post-treatment

60% of patients with MS report sexual dysfunction problems [40] while over 50% experience bowel dysfunction
and up to 75% will report bladder dysfunction [41].
Changes to ambulatory status from baseline classifications were noteworthy in this study for the 25FWT.
Increasing disability (e.g., going from unassisted walking to a cane) is a typical disease progression in the
MS population in general, but the reverse would not
be expected. However, subjects in our study improved
from wheelchair status to using a walker, and from
walker status to requiring no assistance.
In general, QOL for patients with MS is diminished by
physical, emotional, and cognitive symptoms and comorbidities [33, 42]. However, subjects enrolled in this study
reported consistent improvements in their RAND 36 SF
QOL in these areas, particularly at the 1-month evaluation
(p < 0.001). Most categories improved at 1 month, and then
slipped slightly at the 1 year evaluation period while still

remaining improved over baseline, suggesting that treatment frequency greater than once annually could further
improve the treatment subject’s QOL outlook.
Most subjects (83.3%) showed no disease progression
or new lesions in their MRIs. The near complete resolution of the plaques of the brain in one patient (Fig. 7) is
a particularly encouraging finding that should be further
investigated by comparing it to similar MS cohorts in a
standardized time period.
The small sample size is the most significant limitation
of this study in that it may impact the statistical significance of the results. When subjects were lost to followup, the sample size was reduced; due to the nature of
certain tests used to measure efficacy signals, failing to
complete one part of the test often invalidated obtaining
an average for the score. While this issue could have been
avoided with larger recruitment numbers, we are still in
the lower threshold of the 20–80 subjects recommended
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Fig. 7 Changes in magnetic resonance imaging (MRI) before and after treatment. Gadolinium-enhanced MRI scans of the brain for one subject
before (a and c) and after (b and d) treatment. Lesions of interest are indicated by a white arrow. b Interval resolution of a lesion in the right frontal
juxtacortical white matter (a). d Interval resolution of a lesion in the right periatrial white matter (c). Names and other personal information have
been edited out of the images

by FDA for early trials. Additionally, subjects with certain
forms of MS may be less likely to develop new lesions,
which may impact the findings of the reported MRI
results. As this was primarily a safety and proof of concept trial, we did not require subjects to stop their usual
Table 6 Summary of efficacy assessment scores
Test
EDSS mean scores
SNRS bladder/bowel/sexual dysfunction score (normal = 0)

Nine Hole Peg Test—non-dominant hand average scores

Baseline

1 month

1 year

5.2

4.8*

− 4.7

− 2.7*

− 3.1

35.1

30.2*

34.1

medications, which could have a confounding impact on
our findings. Poor medication adherence is frequently
seen among patients with MS (usually because of cost,
perceived lack of efficacy, or adverse effects) [43]; in our
sample, 25% were not taking any MS-specific medication
at the start of treatment. However, it is noteworthy that a
further 20% felt well enough to reduce their intake. In any
case, efficacy of UCMSC therapy for MS should be confirmed with larger, controlled, randomized trials.

4.5*

25-foot walk (second trial) times

17.5

11.5*

13.3

RAND SF-36 average scale

53.5

68.3***

63.5

* p < 0.05 when compared to baseline; *** p < 0.001 when compared to baseline

Conclusions
We have shown that the intravenous infusion of UCMSC
over several days is safe in subjects with MS. Additionally, UCMSC infusions may hold benefits, since this small
study group saw improvement in bladder, bowel, and
sexual dysfunction, walking, upper extremity physical

Riordan et al. J Transl Med (2018) 16:57

function, energy and fatigue, general perspective of a
positive health change and improved quality of life, and
MRI lesions. More clinical studies, particularly with a
larger cohort, are needed to substantiate the specific benefits of UCMSC infusion as a potential MS therapy.
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